CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Optimization of velocity receptor transduction in CAR T cells.
Optimization of velocity receptor transduction in CAR T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
有限的浸润能力显著限制了嵌合抗原受体(CAR)T细胞对实体瘤的疗效。我们最近开发了一大类高度模块化的合成细胞因子受体,称为速度受体(VRs),能够结合关键的炎症细胞因子,如IL5、IL8和TNF,这些细胞因子驱动CAR-T 细胞进入高 motility 状态。这些新型CAR-T 细胞感知并放大这些自分泌分泌的细胞因子,从而维持自我驱动的高迁移状态,促进穿透致密的肿瘤核心。
在本研究中,我们系统评估了影响VR转导的关键因素,以提高其稳定整合和表达。我们建立了一个双荧光报告系统,允许同时监测VR和CAR构建体,同时评估载体构建体的修饰并在各种条件下生成标准化的感染单位(IFU)曲线。
我们的结果表明,通过消除中央多嘌呤束(cPPT)上游的非编码区段来减少整体慢病毒载体大小的尝试并未产生更好的转导效率,尽管尚不清楚该效应是由于病毒生产还是整合受损。
我们还观察到,对于先前在各种人类癌症小鼠模型中测试的一部分VRs,病毒剂量与转导效率之间存在对数线性关系,其中VR5 IL8和VR5 TNF VRs始终优于VR5 IL5和V5(全长天然IL5受体)。
总体而言,这些发现建立了一个优化且可重复的框架,为VR-CAR-T 细胞在实体瘤细胞治疗中的未来开发和功能研究提供了有价值的指导。
Limited infiltration capacity significantly limits the effectiveness of chimeric antigen receptor (CAR) T cells for solid tumors.
We have recently developed a large family of highly modular synthetic cytokine receptors termed velocity receptors (VRs), capable of binding key inflammatory cytokines, such as IL5, IL8, and TNF , which drive CAR T cells into an elevated motility state.
These new CAR T cells sense and amplify these autocrine secreted cytokines, thereby maintaining a self-propelled, high migratory state, facilitating penetration into dense tumor cores. In this study, we systematically evaluated key factors influencing VR transduction in order to improve their stable integration and expression.
We established a dual-fluorescence reporter system to allow simultaneous monitoring of both VR and CAR constructs, and while evaluating modifications to the vector construct and generating standardized infectious unit (IFU) curves under various conditions.
Our results demonstrate that the attempt to reduce overall lentiviral vector size by eliminating non coding sections upstream of the central polypurine tract (cPPT) do not yield better transduction efficiency, though it is unclear if the effect is due to viral production or integration impairment.
We also observed a log-linear relationship between viral dose and transduction efficiency for a subset of VRs previously tested in various mouse models of human cancer, with VR5 IL8 and VR5 TNF VRs consistently outperforming VR5 IL5 and V5 (full length native IL5 receptor).
Overall, these findings establish an optimized and reproducible framework that offers valuable guidance for the future development and functional study of VR-CAR T cells in cellular therapies for solid tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。